Elanco Animal Health stock trades at USD 22.45 after guidance lift

Elanco Animal Health stock was last at USD 22.45 on the NYSE on September 28, 2026 at 4:02 p.m. ET, up USD 0.14, or 0.63 percent, from the previous close. The animal health company is entering the final quarter with higher 2026 revenue and adjusted earnings guidance after its second-quarter performance.

Second-quarter figures beat estimates

According to MarketBeat on September 27, 2026, Elanco reported Q2 revenue of USD 1.37 billion, up 10.2 percent year over year, while adjusted EPS reached USD 0.34 against a USD 0.27 consensus estimate. The standardized Q2 figures put reported revenue at USD 1.368 billion and GAAP net income at USD 54 million for the quarter ended June 30, 2026.

The detailed Q2 earnings call record from The Globe and Mail dated August 5, 2026, showed adjusted EBITDA of USD 288 million, up 21 percent year over year, and adjusted gross margin of 58.1 percent. Innovation revenue contributed USD 340 million, led by Zenrelia and Credelio Quattro.

Guidance moves higher

Elanco's investor-relations page identifies the latest earnings update as a second-quarter 2026 report and says the company raised its full-year outlook. The updated guidance calls for revenue of USD 5.09 billion to USD 5.14 billion, adjusted EBITDA of USD 1.01 billion to USD 1.035 billion and adjusted EPS of USD 1.10 to USD 1.16.

The earnings transcript also sets the 2026 innovation revenue target at USD 1.25 billion and describes a 6 percent to 7 percent organic constant-currency revenue growth range. That combination gives investors a clearer test for the second half: launch momentum must offset continued investment in direct-to-consumer marketing and research.

Analyst target stays above price

MarketBeat reported on September 27, 2026, that eight of 12 covering analysts rated the shares Buy, one rated them Strong Buy and the average 12-month target was USD 29.70. The target lies 32.40 percent above the September 28 price of USD 22.45, leaving deleveraging, margin expansion and product adoption as the main valuation questions.

Market data place ELAN's 52-week range at USD 19.40 to USD 27.98, with September 28 volume at 6,343,259 shares. The stock was 19.74 percent below its 52-week high, while its USD 11.2 billion market capitalization reflects a business still balancing growth investments against debt reduction.

ELAN trades below its yearly high

Elanco Animal Health stock was last at USD 22.45 on the NYSE on September 28, 2026 at 4:02 p.m. ET. Elanco has scheduled its Q3 2026 results call for November 6, 2026, according to StockTitan.

More news and analyses on Elanco Animal Health stock